Incidence and Management of Carfilzomib-induced Cardiovascular Toxicity; A Systematic Review and Meta-analysis

CONCLUSION: Carfilzomib is associated with a significant risk of cardiovascular toxicity and hypertension. With the increasing utilization of carfilzomib, it is critical for primary care physicians, oncologists and cardiologists to be aware of the risk of cardiotoxicity associated with the use of carfilzomib to recognize and treat baseline cardiovascular risk factors in such patients.PMID:33845729 | DOI:10.2174/1871529X21666210412113017

Source: Cardiovascular and Hematological Disorders Drug Targets - April 13, 2021 Category: Drugs & Pharmacology Authors: Azka Latif Vikas Kapoor Noman Lateef Muhammad Junaid Ahsan Rana Mohammad Usman Saad Ullah Malik Naqib Ahmad Nathaniel Rosko Joslyn Rudoni Preethi William Jack Khouri Faiz Anwer Source Type: research